Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

A One-year, Multicenter, Partially Blinded, Double-dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients

This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney organ transplant

Inclusion Criteria

• Male and female patients of any race between 18 to 65 years old (inclusive)
• Patients scheduled to undergo a primary cadaveric or primary non-HLA identical living donor kidney transplantation
• Patients who gave written informed consent to participate in the study Exclusion Criteria
• Recipients of multi-organ transplantation or foreseen to receive a non-renal allograft during the study period
• Graft cold ischemia time greater than 40 hours.
• Patients with pulse rate < 50 beats per minute (bpm) at screening Other protocol-defined exclusion criteria may apply